For the year ending 2025-12-31, ATNM made $90K in revenue. -$33,887K in net income. Net profit margin of -37652.22%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 90 | - | ||
| Research and development, net of reimbursements | 21,124 | 30,045 | ||
| General and administrative | 15,213 | 12,076 | ||
| Total operating expenses | 36,337 | 42,121 | ||
| Loss from operations | -36,247 | -42,121 | ||
| Interest income net | 2,360 | 3,878 | ||
| Total other income | 2,360 | 3,878 | ||
| Net loss | -33,887 | -38,243 | ||
| Basic EPS | -1.09 | -1.27 | ||
| Diluted EPS | -1.09 | -1.27 | ||
| Basic Average Shares | 31,195,891 | 30,070,028 | ||
| Diluted Average Shares | 31,195,891 | 30,070,028 | ||
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM)